#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Functional connectomics of affective and psychotic pathology Significance Historically, most research on the biological origins of psychiatric illness has focused on individual diagnostic categories, studied in isolation.
1-1	0-10	Functional	_
1-2	11-23	connectomics	_
1-3	24-26	of	_
1-4	27-36	affective	_
1-5	37-40	and	_
1-6	41-50	psychotic	_
1-7	51-60	pathology	_
1-8	61-73	Significance	_
1-9	74-86	Historically	_
1-10	87-88	,	_
1-11	89-93	most	_
1-12	94-102	research	_
1-13	103-105	on	_
1-14	106-109	the	_
1-15	110-120	biological	_
1-16	121-128	origins	_
1-17	129-131	of	_
1-18	132-143	psychiatric	_
1-19	144-151	illness	_
1-20	152-155	has	_
1-21	156-163	focused	_
1-22	164-166	on	_
1-23	167-177	individual	_
1-24	178-188	diagnostic	_
1-25	189-199	categories	_
1-26	200-201	,	_
1-27	202-209	studied	_
1-28	210-212	in	_
1-29	213-222	isolation	_
1-30	223-224	.	_

Text=Mounting evidence indicates that nominally distinct psychiatric diagnoses are not separated by clear neurobiological boundaries.
2-1	225-233	Mounting	_
2-2	234-242	evidence	_
2-3	243-252	indicates	_
2-4	253-257	that	_
2-5	258-267	nominally	_
2-6	268-276	distinct	_
2-7	277-288	psychiatric	_
2-8	289-298	diagnoses	_
2-9	299-302	are	_
2-10	303-306	not	_
2-11	307-316	separated	_
2-12	317-319	by	_
2-13	320-325	clear	_
2-14	326-341	neurobiological	_
2-15	342-352	boundaries	_
2-16	353-354	.	_

Text=Here, we derive functional connectomic signatures in over 1,000 individuals, including patients presenting with different categories of impairment (psychosis), clinical diagnoses, and severity of illness as reflected in treatment seeking.
3-1	355-359	Here	_
3-2	360-361	,	_
3-3	362-364	we	_
3-4	365-371	derive	_
3-5	372-382	functional	_
3-6	383-394	connectomic	_
3-7	395-405	signatures	_
3-8	406-408	in	_
3-9	409-413	over	_
3-10	414-419	1,000	_
3-11	420-431	individuals	_
3-12	432-433	,	_
3-13	434-443	including	_
3-14	444-452	patients	_
3-15	453-463	presenting	_
3-16	464-468	with	_
3-17	469-478	different	_
3-18	479-489	categories	_
3-19	490-492	of	_
3-20	493-503	impairment	_
3-21	504-505	(	_
3-22	506-515	psychosis	_
3-23	516-517	)	_
3-24	518-519	,	_
3-25	520-528	clinical	_
3-26	529-538	diagnoses	_
3-27	539-540	,	_
3-28	541-544	and	_
3-29	545-553	severity	_
3-30	554-556	of	_
3-31	557-564	illness	_
3-32	565-567	as	_
3-33	568-577	reflected	_
3-34	578-580	in	_
3-35	581-590	treatment	_
3-36	591-598	seeking	_
3-37	599-600	.	_

Text=Our analyses reveal features of connectome functioning that are commonly disrupted across distinct forms of pathology, scaling with clinical severity.
4-1	601-604	Our	_
4-2	605-613	analyses	_
4-3	614-620	reveal	_
4-4	621-629	features	_
4-5	630-632	of	_
4-6	633-643	connectome	_
4-7	644-655	functioning	_
4-8	656-660	that	_
4-9	661-664	are	_
4-10	665-673	commonly	_
4-11	674-683	disrupted	_
4-12	684-690	across	_
4-13	691-699	distinct	_
4-14	700-705	forms	_
4-15	706-708	of	_
4-16	709-718	pathology	_
4-17	719-720	,	_
4-18	721-728	scaling	_
4-19	729-733	with	_
4-20	734-742	clinical	_
4-21	743-751	severity	_
4-22	752-753	.	_

Text=Conversely, other aspects of network connectivity were preferentially disrupted in patients with psychotic illness.
5-1	754-764	Conversely	_
5-2	765-766	,	_
5-3	767-772	other	_
5-4	773-780	aspects	_
5-5	781-783	of	_
5-6	784-791	network	_
5-7	792-804	connectivity	_
5-8	805-809	were	_
5-9	810-824	preferentially	_
5-10	825-834	disrupted	_
5-11	835-837	in	_
5-12	838-846	patients	_
5-13	847-851	with	_
5-14	852-861	psychotic	_
5-15	862-869	illness	_
5-16	870-871	.	_

Text=These data have important implications for the establishment of functional connectome fingerprints of severe mental disease.
6-1	872-877	These	_
6-2	878-882	data	_
6-3	883-887	have	_
6-4	888-897	important	_
6-5	898-910	implications	_
6-6	911-914	for	_
6-7	915-918	the	_
6-8	919-932	establishment	_
6-9	933-935	of	_
6-10	936-946	functional	_
6-11	947-957	connectome	_
6-12	958-970	fingerprints	_
6-13	971-973	of	_
6-14	974-980	severe	_
6-15	981-987	mental	_
6-16	988-995	disease	_
6-17	996-997	.	_

Text=Converging evidence indicates that groups of patients with nominally distinct psychiatric diagnoses are not separated by sharp or discontinuous neurobiological boundaries.
7-1	998-1008	Converging	_
7-2	1009-1017	evidence	_
7-3	1018-1027	indicates	_
7-4	1028-1032	that	_
7-5	1033-1039	groups	_
7-6	1040-1042	of	_
7-7	1043-1051	patients	_
7-8	1052-1056	with	_
7-9	1057-1066	nominally	_
7-10	1067-1075	distinct	_
7-11	1076-1087	psychiatric	_
7-12	1088-1097	diagnoses	_
7-13	1098-1101	are	_
7-14	1102-1105	not	_
7-15	1106-1115	separated	_
7-16	1116-1118	by	_
7-17	1119-1124	sharp	_
7-18	1125-1127	or	_
7-19	1128-1141	discontinuous	_
7-20	1142-1157	neurobiological	_
7-21	1158-1168	boundaries	_
7-22	1169-1170	.	_

Text=In healthy populations, individual differences in behavior are reflected in variability across the collective set of functional brain connections (functional connectome).
8-1	1171-1173	In	_
8-2	1174-1181	healthy	_
8-3	1182-1193	populations	_
8-4	1194-1195	,	_
8-5	1196-1206	individual	_
8-6	1207-1218	differences	_
8-7	1219-1221	in	_
8-8	1222-1230	behavior	_
8-9	1231-1234	are	_
8-10	1235-1244	reflected	_
8-11	1245-1247	in	_
8-12	1248-1259	variability	_
8-13	1260-1266	across	_
8-14	1267-1270	the	_
8-15	1271-1281	collective	_
8-16	1282-1285	set	_
8-17	1286-1288	of	_
8-18	1289-1299	functional	_
8-19	1300-1305	brain	_
8-20	1306-1317	connections	_
8-21	1318-1319	(	_
8-22	1320-1330	functional	_
8-23	1331-1341	connectome	_
8-24	1342-1343	)	_
8-25	1344-1345	.	_

Text=These data suggest that the spectra of transdiagnostic symptom profiles observed in psychiatric patients may map onto detectable patterns of network function.
9-1	1346-1351	These	_
9-2	1352-1356	data	_
9-3	1357-1364	suggest	_
9-4	1365-1369	that	_
9-5	1370-1373	the	_
9-6	1374-1381	spectra	_
9-7	1382-1384	of	_
9-8	1385-1400	transdiagnostic	_
9-9	1401-1408	symptom	_
9-10	1409-1417	profiles	_
9-11	1418-1426	observed	_
9-12	1427-1429	in	_
9-13	1430-1441	psychiatric	_
9-14	1442-1450	patients	_
9-15	1451-1454	may	_
9-16	1455-1458	map	_
9-17	1459-1463	onto	_
9-18	1464-1474	detectable	_
9-19	1475-1483	patterns	_
9-20	1484-1486	of	_
9-21	1487-1494	network	_
9-22	1495-1503	function	_
9-23	1504-1505	.	_

Text=To examine the manner through which neurobiological variation might underlie clinical presentation, we obtained fMRI data from over 1,000 individuals, including 210 diagnosed with a primary psychotic disorder or affective psychosis (bipolar disorder with psychosis and schizophrenia or schizoaffective disorder), 192 presenting with a primary affective disorder without psychosis (unipolar depression, bipolar disorder without psychosis), and 608 demographically matched healthy comparison participants recruited through a large-scale study of brain imaging and genetics.
10-1	1506-1508	To	_
10-2	1509-1516	examine	_
10-3	1517-1520	the	_
10-4	1521-1527	manner	_
10-5	1528-1535	through	_
10-6	1536-1541	which	_
10-7	1542-1557	neurobiological	_
10-8	1558-1567	variation	_
10-9	1568-1573	might	_
10-10	1574-1582	underlie	_
10-11	1583-1591	clinical	_
10-12	1592-1604	presentation	_
10-13	1605-1606	,	_
10-14	1607-1609	we	_
10-15	1610-1618	obtained	_
10-16	1619-1623	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
10-17	1624-1628	data	_
10-18	1629-1633	from	_
10-19	1634-1638	over	_
10-20	1639-1644	1,000	_
10-21	1645-1656	individuals	_
10-22	1657-1658	,	_
10-23	1659-1668	including	_
10-24	1669-1672	210	_
10-25	1673-1682	diagnosed	_
10-26	1683-1687	with	_
10-27	1688-1689	a	_
10-28	1690-1697	primary	_
10-29	1698-1707	psychotic	_
10-30	1708-1716	disorder	_
10-31	1717-1719	or	_
10-32	1720-1729	affective	_
10-33	1730-1739	psychosis	_
10-34	1740-1741	(	_
10-35	1742-1749	bipolar	_
10-36	1750-1758	disorder	_
10-37	1759-1763	with	_
10-38	1764-1773	psychosis	_
10-39	1774-1777	and	_
10-40	1778-1791	schizophrenia	_
10-41	1792-1794	or	_
10-42	1795-1810	schizoaffective	_
10-43	1811-1819	disorder	_
10-44	1820-1821	)	_
10-45	1822-1823	,	_
10-46	1824-1827	192	_
10-47	1828-1838	presenting	_
10-48	1839-1843	with	_
10-49	1844-1845	a	_
10-50	1846-1853	primary	_
10-51	1854-1863	affective	_
10-52	1864-1872	disorder	_
10-53	1873-1880	without	_
10-54	1881-1890	psychosis	_
10-55	1891-1892	(	_
10-56	1893-1901	unipolar	_
10-57	1902-1912	depression	_
10-58	1913-1914	,	_
10-59	1915-1922	bipolar	_
10-60	1923-1931	disorder	_
10-61	1932-1939	without	_
10-62	1940-1949	psychosis	_
10-63	1950-1951	)	_
10-64	1952-1953	,	_
10-65	1954-1957	and	_
10-66	1958-1961	608	_
10-67	1962-1977	demographically	_
10-68	1978-1985	matched	_
10-69	1986-1993	healthy	_
10-70	1994-2004	comparison	_
10-71	2005-2017	participants	_
10-72	2018-2027	recruited	_
10-73	2028-2035	through	_
10-74	2036-2037	a	_
10-75	2038-2049	large-scale	_
10-76	2050-2055	study	_
10-77	2056-2058	of	_
10-78	2059-2064	brain	_
10-79	2065-2072	imaging	_
10-80	2073-2076	and	_
10-81	2077-2085	genetics	_
10-82	2086-2087	.	_

Text=Here, we examine variation in functional connectomes across psychiatric diagnoses, finding striking evidence for disease connectomic “ fingerprints ” that are commonly disrupted across distinct forms of pathology and appear to scale as a function of illness severity.
11-1	2088-2092	Here	_
11-2	2093-2094	,	_
11-3	2095-2097	we	_
11-4	2098-2105	examine	_
11-5	2106-2115	variation	_
11-6	2116-2118	in	_
11-7	2119-2129	functional	_
11-8	2130-2141	connectomes	_
11-9	2142-2148	across	_
11-10	2149-2160	psychiatric	_
11-11	2161-2170	diagnoses	_
11-12	2171-2172	,	_
11-13	2173-2180	finding	_
11-14	2181-2189	striking	_
11-15	2190-2198	evidence	_
11-16	2199-2202	for	_
11-17	2203-2210	disease	_
11-18	2211-2222	connectomic	_
11-19	2223-2224	“	_
11-20	2225-2237	fingerprints	_
11-21	2238-2239	”	_
11-22	2240-2244	that	_
11-23	2245-2248	are	_
11-24	2249-2257	commonly	_
11-25	2258-2267	disrupted	_
11-26	2268-2274	across	_
11-27	2275-2283	distinct	_
11-28	2284-2289	forms	_
11-29	2290-2292	of	_
11-30	2293-2302	pathology	_
11-31	2303-2306	and	_
11-32	2307-2313	appear	_
11-33	2314-2316	to	_
11-34	2317-2322	scale	_
11-35	2323-2325	as	_
11-36	2326-2327	a	_
11-37	2328-2336	function	_
11-38	2337-2339	of	_
11-39	2340-2347	illness	_
11-40	2348-2356	severity	_
11-41	2357-2358	.	_

Text=The presence of affective and psychotic illnesses was associated with graded disruptions in frontoparietal network connectivity (encompassing aspects of dorsolateral prefrontal, dorsomedial prefrontal, lateral parietal, and posterior temporal cortices).
12-1	2359-2362	The	_
12-2	2363-2371	presence	_
12-3	2372-2374	of	_
12-4	2375-2384	affective	_
12-5	2385-2388	and	_
12-6	2389-2398	psychotic	_
12-7	2399-2408	illnesses	_
12-8	2409-2412	was	_
12-9	2413-2423	associated	_
12-10	2424-2428	with	_
12-11	2429-2435	graded	_
12-12	2436-2447	disruptions	_
12-13	2448-2450	in	_
12-14	2451-2465	frontoparietal	_
12-15	2466-2473	network	_
12-16	2474-2486	connectivity	_
12-17	2487-2488	(	_
12-18	2489-2501	encompassing	_
12-19	2502-2509	aspects	_
12-20	2510-2512	of	_
12-21	2513-2525	dorsolateral	_
12-22	2526-2536	prefrontal	_
12-23	2537-2538	,	_
12-24	2539-2550	dorsomedial	_
12-25	2551-2561	prefrontal	_
12-26	2562-2563	,	_
12-27	2564-2571	lateral	_
12-28	2572-2580	parietal	_
12-29	2581-2582	,	_
12-30	2583-2586	and	_
12-31	2587-2596	posterior	_
12-32	2597-2605	temporal	_
12-33	2606-2614	cortices	_
12-34	2615-2616	)	_
12-35	2617-2618	.	_

Text=Conversely, other properties of network connectivity, including default network integrity, were preferentially disrupted in patients with psychotic illness, but not patients without psychotic symptoms.
13-1	2619-2629	Conversely	_
13-2	2630-2631	,	_
13-3	2632-2637	other	_
13-4	2638-2648	properties	_
13-5	2649-2651	of	_
13-6	2652-2659	network	_
13-7	2660-2672	connectivity	_
13-8	2673-2674	,	_
13-9	2675-2684	including	_
13-10	2685-2692	default	_
13-11	2693-2700	network	_
13-12	2701-2710	integrity	_
13-13	2711-2712	,	_
13-14	2713-2717	were	_
13-15	2718-2732	preferentially	_
13-16	2733-2742	disrupted	_
13-17	2743-2745	in	_
13-18	2746-2754	patients	_
13-19	2755-2759	with	_
13-20	2760-2769	psychotic	_
13-21	2770-2777	illness	_
13-22	2778-2779	,	_
13-23	2780-2783	but	_
13-24	2784-2787	not	_
13-25	2788-2796	patients	_
13-26	2797-2804	without	_
13-27	2805-2814	psychotic	_
13-28	2815-2823	symptoms	_
13-29	2824-2825	.	_

Text=This work allows us to establish key biological and clinical features of the functional connectomes of severe mental disease.
14-1	2826-2830	This	_
14-2	2831-2835	work	_
14-3	2836-2842	allows	_
14-4	2843-2845	us	_
14-5	2846-2848	to	_
14-6	2849-2858	establish	_
14-7	2859-2862	key	_
14-8	2863-2873	biological	_
14-9	2874-2877	and	_
14-10	2878-2886	clinical	_
14-11	2887-2895	features	_
14-12	2896-2898	of	_
14-13	2899-2902	the	_
14-14	2903-2913	functional	_
14-15	2914-2925	connectomes	_
14-16	2926-2928	of	_
14-17	2929-2935	severe	_
14-18	2936-2942	mental	_
14-19	2943-2950	disease	_
14-20	2951-2952	.	_

Text=Methods Between November 2008 and June 2017, fMRI data were collected from a total of 1,010 individuals, including 210 diagnosed with a primary psychotic disorder (137 meeting criteria for schizophrenia or schizoaffective disorder, 73 with bipolar disorder with psychosis), 192 presenting with a primary affective disorder without psychosis (26 with bipolar disorder without psychosis, 57 treatment-seeking individuals with unipolar depression, 109 nontreatment-seeking individuals with unipolar depression), and 608 demographically matched healthy comparison participants recruited through an ongoing, large-scale study of brain imaging and genetics.
15-1	2953-2960	Methods	_
15-2	2961-2968	Between	_
15-3	2969-2977	November	_
15-4	2978-2982	2008	_
15-5	2983-2986	and	_
15-6	2987-2991	June	_
15-7	2992-2996	2017	_
15-8	2997-2998	,	_
15-9	2999-3003	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
15-10	3004-3008	data	_
15-11	3009-3013	were	_
15-12	3014-3023	collected	_
15-13	3024-3028	from	_
15-14	3029-3030	a	_
15-15	3031-3036	total	_
15-16	3037-3039	of	_
15-17	3040-3045	1,010	_
15-18	3046-3057	individuals	_
15-19	3058-3059	,	_
15-20	3060-3069	including	_
15-21	3070-3073	210	_
15-22	3074-3083	diagnosed	_
15-23	3084-3088	with	_
15-24	3089-3090	a	_
15-25	3091-3098	primary	_
15-26	3099-3108	psychotic	_
15-27	3109-3117	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
15-28	3118-3119	(	_
15-29	3120-3123	137	_
15-30	3124-3131	meeting	_
15-31	3132-3140	criteria	_
15-32	3141-3144	for	_
15-33	3145-3158	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-34	3159-3161	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-35	3162-3177	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
15-36	3178-3186	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
15-37	3187-3188	,	_
15-38	3189-3191	73	_
15-39	3192-3196	with	_
15-40	3197-3204	bipolar	_
15-41	3205-3213	disorder	_
15-42	3214-3218	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
15-43	3219-3228	psychosis	_
15-44	3229-3230	)	_
15-45	3231-3232	,	_
15-46	3233-3236	192	_
15-47	3237-3247	presenting	_
15-48	3248-3252	with	_
15-49	3253-3254	a	_
15-50	3255-3262	primary	_
15-51	3263-3272	affective	_
15-52	3273-3281	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
15-53	3282-3289	without	_
15-54	3290-3299	psychosis	_
15-55	3300-3301	(	_
15-56	3302-3304	26	_
15-57	3305-3309	with	_
15-58	3310-3317	bipolar	_
15-59	3318-3326	disorder	http://maven.renci.org/NeuroBridge/neurobridge#OppositionalDefiantDisorder
15-60	3327-3334	without	http://maven.renci.org/NeuroBridge/neurobridge#OppositionalDefiantDisorder
15-61	3335-3344	psychosis	_
15-62	3345-3346	,	_
15-63	3347-3349	57	_
15-64	3350-3367	treatment-seeking	_
15-65	3368-3379	individuals	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-66	3380-3384	with	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-67	3385-3393	unipolar	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-68	3394-3404	depression	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-69	3405-3406	,	_
15-70	3407-3410	109	_
15-71	3411-3431	nontreatment-seeking	_
15-72	3432-3443	individuals	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-73	3444-3448	with	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-74	3449-3457	unipolar	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-75	3458-3468	depression	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-76	3469-3470	)	_
15-77	3471-3472	,	_
15-78	3473-3476	and	_
15-79	3477-3480	608	_
15-80	3481-3496	demographically	_
15-81	3497-3504	matched	_
15-82	3505-3512	healthy	_
15-83	3513-3523	comparison	_
15-84	3524-3536	participants	_
15-85	3537-3546	recruited	_
15-86	3547-3554	through	_
15-87	3555-3557	an	_
15-88	3558-3565	ongoing	_
15-89	3566-3567	,	_
15-90	3568-3579	large-scale	_
15-91	3580-3585	study	_
15-92	3586-3588	of	_
15-93	3589-3594	brain	_
15-94	3595-3602	imaging	_
15-95	3603-3606	and	_
15-96	3607-3615	genetics	_
15-97	3616-3617	.	_

Text=Diagnosis was determined using the Structured Clinical Interview for the DSM-IV.
16-1	3618-3627	Diagnosis	_
16-2	3628-3631	was	_
16-3	3632-3642	determined	_
16-4	3643-3648	using	_
16-5	3649-3652	the	_
16-6	3653-3663	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-7	3664-3672	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-8	3673-3682	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-9	3683-3686	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-10	3687-3690	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-11	3691-3697	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-12	3698-3699	.	_

Text=Details regarding participant recruitment and characterization, as well as the demographic and clinical characteristics of the patient and matched healthy comparison samples, are available in SI Appendix, Table S1.
17-1	3700-3707	Details	_
17-2	3708-3717	regarding	_
17-3	3718-3729	participant	_
17-4	3730-3741	recruitment	_
17-5	3742-3745	and	_
17-6	3746-3762	characterization	_
17-7	3763-3764	,	_
17-8	3765-3767	as	_
17-9	3768-3772	well	_
17-10	3773-3775	as	_
17-11	3776-3779	the	_
17-12	3780-3791	demographic	_
17-13	3792-3795	and	_
17-14	3796-3804	clinical	_
17-15	3805-3820	characteristics	_
17-16	3821-3823	of	_
17-17	3824-3827	the	_
17-18	3828-3835	patient	_
17-19	3836-3839	and	_
17-20	3840-3847	matched	_
17-21	3848-3855	healthy	_
17-22	3856-3866	comparison	_
17-23	3867-3874	samples	_
17-24	3875-3876	,	_
17-25	3877-3880	are	_
17-26	3881-3890	available	_
17-27	3891-3893	in	_
17-28	3894-3896	SI	_
17-29	3897-3905	Appendix	_
17-30	3906-3907	,	_
17-31	3908-3913	Table	_
17-32	3914-3916	S1	_
17-33	3917-3918	.	_

Text=In brief, patients were recruited from clinical services at MGH or McLean Hospital through the procedures detailed in Baker et al .. Nontreatment-seeking individuals who met diagnostic criteria for unipolar depression were recruited from the surrounding Boston area using the procedures detailed in Dillon et al ..
18-1	3919-3921	In	_
18-2	3922-3927	brief	_
18-3	3928-3929	,	_
18-4	3930-3938	patients	_
18-5	3939-3943	were	_
18-6	3944-3953	recruited	_
18-7	3954-3958	from	_
18-8	3959-3967	clinical	_
18-9	3968-3976	services	_
18-10	3977-3979	at	_
18-11	3980-3983	MGH	_
18-12	3984-3986	or	_
18-13	3987-3993	McLean	_
18-14	3994-4002	Hospital	_
18-15	4003-4010	through	_
18-16	4011-4014	the	_
18-17	4015-4025	procedures	_
18-18	4026-4034	detailed	_
18-19	4035-4037	in	_
18-20	4038-4043	Baker	_
18-21	4044-4046	et	_
18-22	4047-4049	al	_
18-23	4050-4052	..	_
18-24	4053-4073	Nontreatment-seeking	_
18-25	4074-4085	individuals	_
18-26	4086-4089	who	_
18-27	4090-4093	met	_
18-28	4094-4104	diagnostic	_
18-29	4105-4113	criteria	_
18-30	4114-4117	for	_
18-31	4118-4126	unipolar	_
18-32	4127-4137	depression	_
18-33	4138-4142	were	_
18-34	4143-4152	recruited	_
18-35	4153-4157	from	_
18-36	4158-4161	the	_
18-37	4162-4173	surrounding	_
18-38	4174-4180	Boston	_
18-39	4181-4185	area	_
18-40	4186-4191	using	_
18-41	4192-4195	the	_
18-42	4196-4206	procedures	_
18-43	4207-4215	detailed	_
18-44	4216-4218	in	_
18-45	4219-4225	Dillon	_
18-46	4226-4228	et	_
18-47	4229-4231	al	_
18-48	4232-4234	..	_

Text=Healthy comparison participants were selected from an existing database of adults (aged 18–83 y), scanned previously using identical pulse sequences on identical scanners, and selected to match patients on the basis of age, gender, race, handedness, as well as a mean slice-based signal-to-noise ratio (SNR) derived from the participant ’ s blood oxygenation level–dependent (BOLD) T2 * image series.
19-1	4235-4242	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#Comparison
19-2	4243-4253	comparison	http://maven.renci.org/NeuroBridge/neurobridge#Comparison
19-3	4254-4266	participants	_
19-4	4267-4271	were	_
19-5	4272-4280	selected	_
19-6	4281-4285	from	_
19-7	4286-4288	an	_
19-8	4289-4297	existing	_
19-9	4298-4306	database	_
19-10	4307-4309	of	_
19-11	4310-4316	adults	_
19-12	4317-4318	(	_
19-13	4319-4323	aged	_
19-14	4324-4329	18–83	_
19-15	4330-4331	y	_
19-16	4332-4333	)	_
19-17	4334-4335	,	_
19-18	4336-4343	scanned	_
19-19	4344-4354	previously	_
19-20	4355-4360	using	_
19-21	4361-4370	identical	_
19-22	4371-4376	pulse	_
19-23	4377-4386	sequences	_
19-24	4387-4389	on	_
19-25	4390-4399	identical	_
19-26	4400-4408	scanners	_
19-27	4409-4410	,	_
19-28	4411-4414	and	_
19-29	4415-4423	selected	_
19-30	4424-4426	to	_
19-31	4427-4432	match	_
19-32	4433-4441	patients	_
19-33	4442-4444	on	_
19-34	4445-4448	the	_
19-35	4449-4454	basis	_
19-36	4455-4457	of	_
19-37	4458-4461	age	_
19-38	4462-4463	,	_
19-39	4464-4470	gender	_
19-40	4471-4472	,	_
19-41	4473-4477	race	_
19-42	4478-4479	,	_
19-43	4480-4490	handedness	_
19-44	4491-4492	,	_
19-45	4493-4495	as	_
19-46	4496-4500	well	_
19-47	4501-4503	as	_
19-48	4504-4505	a	_
19-49	4506-4510	mean	_
19-50	4511-4522	slice-based	_
19-51	4523-4538	signal-to-noise	_
19-52	4539-4544	ratio	_
19-53	4545-4546	(	_
19-54	4547-4550	SNR	_
19-55	4551-4552	)	_
19-56	4553-4560	derived	_
19-57	4561-4565	from	_
19-58	4566-4569	the	_
19-59	4570-4581	participant	_
19-60	4582-4583	’	_
19-61	4584-4585	s	_
19-62	4586-4591	blood	_
19-63	4592-4603	oxygenation	_
19-64	4604-4619	level–dependent	_
19-65	4620-4621	(	_
19-66	4622-4626	BOLD	_
19-67	4627-4628	)	_
19-68	4629-4631	T2	_
19-69	4632-4633	*	_
19-70	4634-4639	image	_
19-71	4640-4646	series	_
19-72	4647-4648	.	_

Text=In this context, SNR is calculated as the mean/SD of the mean slice intensity time series.
20-1	4649-4651	In	_
20-2	4652-4656	this	_
20-3	4657-4664	context	_
20-4	4665-4666	,	_
20-5	4667-4670	SNR	_
20-6	4671-4673	is	_
20-7	4674-4684	calculated	_
20-8	4685-4687	as	_
20-9	4688-4691	the	_
20-10	4692-4699	mean/SD	_
20-11	4700-4702	of	_
20-12	4703-4706	the	_
20-13	4707-4711	mean	_
20-14	4712-4717	slice	_
20-15	4718-4727	intensity	_
20-16	4728-4732	time	_
20-17	4733-4739	series	_
20-18	4740-4741	.	_

Text=Using this strategy, we were able to ensure statistically matched distributions for both demographic variables and comparable data quality (as well as head movement metrics).
21-1	4742-4747	Using	_
21-2	4748-4752	this	_
21-3	4753-4761	strategy	_
21-4	4762-4763	,	_
21-5	4764-4766	we	_
21-6	4767-4771	were	_
21-7	4772-4776	able	_
21-8	4777-4779	to	_
21-9	4780-4786	ensure	_
21-10	4787-4800	statistically	_
21-11	4801-4808	matched	_
21-12	4809-4822	distributions	_
21-13	4823-4826	for	_
21-14	4827-4831	both	_
21-15	4832-4843	demographic	_
21-16	4844-4853	variables	_
21-17	4854-4857	and	_
21-18	4858-4868	comparable	_
21-19	4869-4873	data	_
21-20	4874-4881	quality	_
21-21	4882-4883	(	_
21-22	4884-4886	as	_
21-23	4887-4891	well	_
21-24	4892-4894	as	_
21-25	4895-4899	head	_
21-26	4900-4908	movement	_
21-27	4909-4916	metrics	_
21-28	4917-4918	)	_
21-29	4919-4920	.	_

Text=The reported experiments were approved by the Partners HealthCare Institutional Review Board and the Harvard University Committee on the Use of Human Subjects in Research McLean Hospital Institutional Review Board, and all participants gave written informed consent before participating in the study.
22-1	4921-4924	The	_
22-2	4925-4933	reported	_
22-3	4934-4945	experiments	_
22-4	4946-4950	were	_
22-5	4951-4959	approved	_
22-6	4960-4962	by	_
22-7	4963-4966	the	_
22-8	4967-4975	Partners	_
22-9	4976-4986	HealthCare	_
22-10	4987-5000	Institutional	_
22-11	5001-5007	Review	_
22-12	5008-5013	Board	_
22-13	5014-5017	and	_
22-14	5018-5021	the	_
22-15	5022-5029	Harvard	_
22-16	5030-5040	University	_
22-17	5041-5050	Committee	_
22-18	5051-5053	on	_
22-19	5054-5057	the	_
22-20	5058-5061	Use	_
22-21	5062-5064	of	_
22-22	5065-5070	Human	_
22-23	5071-5079	Subjects	_
22-24	5080-5082	in	_
22-25	5083-5091	Research	_
22-26	5092-5098	McLean	_
22-27	5099-5107	Hospital	_
22-28	5108-5121	Institutional	_
22-29	5122-5128	Review	_
22-30	5129-5134	Board	_
22-31	5135-5136	,	_
22-32	5137-5140	and	_
22-33	5141-5144	all	_
22-34	5145-5157	participants	_
22-35	5158-5162	gave	_
22-36	5163-5170	written	_
22-37	5171-5179	informed	_
22-38	5180-5187	consent	_
22-39	5188-5194	before	_
22-40	5195-5208	participating	_
22-41	5209-5211	in	_
22-42	5212-5215	the	_
22-43	5216-5221	study	_
22-44	5222-5223	.	_

Text=MRI Data Acquisition.
23-1	5224-5227	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-2	5228-5232	Data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-3	5233-5244	Acquisition	_
23-4	5245-5246	.	_

Text=Imaging data were collected on 3T Tim Trio scanners (Siemens) using either 12- or 32-channel phased-array head coils at Harvard University, MGH, or McLean Hospital as detailed in Holmes et al ..
24-1	5247-5254	Imaging	_
24-2	5255-5259	data	_
24-3	5260-5264	were	_
24-4	5265-5274	collected	_
24-5	5275-5277	on	_
24-6	5278-5280	3T	_
24-7	5281-5284	Tim	_
24-8	5285-5289	Trio	_
24-9	5290-5298	scanners	_
24-10	5299-5300	(	_
24-11	5301-5308	Siemens	_
24-12	5309-5310	)	_
24-13	5311-5316	using	_
24-14	5317-5323	either	_
24-15	5324-5327	12-	_
24-16	5328-5330	or	_
24-17	5331-5341	32-channel	_
24-18	5342-5354	phased-array	_
24-19	5355-5359	head	_
24-20	5360-5365	coils	_
24-21	5366-5368	at	_
24-22	5369-5376	Harvard	_
24-23	5377-5387	University	_
24-24	5388-5389	,	_
24-25	5390-5393	MGH	_
24-26	5394-5395	,	_
24-27	5396-5398	or	_
24-28	5399-5405	McLean	_
24-29	5406-5414	Hospital	_
24-30	5415-5417	as	_
24-31	5418-5426	detailed	_
24-32	5427-5429	in	_
24-33	5430-5436	Holmes	_
24-34	5437-5439	et	_
24-35	5440-5442	al	_
24-36	5443-5445	..	_

Text=Briefly, structural data included a high-resolution, multiecho T1-weighted magnetization-prepared gradient-echo image [144 slices, repetition time (TR) = 2,200 ms, inversion time (TI) = 1,100 ms, echo time (TE) = 1.54 ms for image 1 to 7.01 ms for image 4, flip angle = 7°, voxels = 1.2 mm3, field-of-view (FOV) = 230].
25-1	5446-5453	Briefly	_
25-2	5454-5455	,	_
25-3	5456-5466	structural	_
25-4	5467-5471	data	_
25-5	5472-5480	included	_
25-6	5481-5482	a	_
25-7	5483-5498	high-resolution	_
25-8	5499-5500	,	_
25-9	5501-5510	multiecho	_
25-10	5511-5522	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-11	5523-5545	magnetization-prepared	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-12	5546-5559	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
25-13	5560-5565	image	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
25-14	5566-5567	[	_
25-15	5568-5571	144	_
25-16	5572-5578	slices	_
25-17	5579-5580	,	_
25-18	5581-5591	repetition	_
25-19	5592-5596	time	_
25-20	5597-5598	(	_
25-21	5599-5601	TR	_
25-22	5602-5603	)	_
25-23	5604-5605	=	_
25-24	5606-5611	2,200	_
25-25	5612-5614	ms	_
25-26	5615-5616	,	_
25-27	5617-5626	inversion	_
25-28	5627-5631	time	_
25-29	5632-5633	(	_
25-30	5634-5636	TI	_
25-31	5637-5638	)	_
25-32	5639-5640	=	_
25-33	5641-5646	1,100	_
25-34	5647-5649	ms	_
25-35	5650-5651	,	_
25-36	5652-5656	echo	_
25-37	5657-5661	time	_
25-38	5662-5663	(	_
25-39	5664-5666	TE	_
25-40	5667-5668	)	_
25-41	5669-5670	=	_
25-42	5671-5675	1.54	_
25-43	5676-5678	ms	_
25-44	5679-5682	for	_
25-45	5683-5688	image	_
25-46	5689-5690	1	_
25-47	5691-5693	to	_
25-48	5694-5698	7.01	_
25-49	5699-5701	ms	_
25-50	5702-5705	for	_
25-51	5706-5711	image	_
25-52	5712-5713	4	_
25-53	5714-5715	,	_
25-54	5716-5720	flip	_
25-55	5721-5726	angle	_
25-56	5727-5728	=	_
25-57	5729-5731	7°	_
25-58	5732-5733	,	_
25-59	5734-5740	voxels	_
25-60	5741-5742	=	_
25-61	5743-5746	1.2	_
25-62	5747-5750	mm3	_
25-63	5751-5752	,	_
25-64	5753-5766	field-of-view	_
25-65	5767-5768	(	_
25-66	5769-5772	FOV	_
25-67	5773-5774	)	_
25-68	5775-5776	=	_
25-69	5777-5780	230	_
25-70	5781-5782	]	_
25-71	5783-5784	.	_

Text=Functional data were acquired using a gradient-echo echoplanar imaging sequence (47 axial slices, interleaved with no gap), 124 time points (TR = 3000 ms, TE = 30 ms, flip angle = 85°, voxels = 3 mm3, FOV = 216).
26-1	5785-5795	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
26-2	5796-5800	data	_
26-3	5801-5805	were	_
26-4	5806-5814	acquired	_
26-5	5815-5820	using	_
26-6	5821-5822	a	_
26-7	5823-5836	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-8	5837-5847	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-9	5848-5855	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-10	5856-5864	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-11	5865-5866	(	_
26-12	5867-5869	47	_
26-13	5870-5875	axial	_
26-14	5876-5882	slices	_
26-15	5883-5884	,	_
26-16	5885-5896	interleaved	_
26-17	5897-5901	with	_
26-18	5902-5904	no	_
26-19	5905-5908	gap	_
26-20	5909-5910	)	_
26-21	5911-5912	,	_
26-22	5913-5916	124	_
26-23	5917-5921	time	_
26-24	5922-5928	points	_
26-25	5929-5930	(	_
26-26	5931-5933	TR	_
26-27	5934-5935	=	_
26-28	5936-5940	3000	_
26-29	5941-5943	ms	_
26-30	5944-5945	,	_
26-31	5946-5948	TE	_
26-32	5949-5950	=	_
26-33	5951-5953	30	_
26-34	5954-5956	ms	_
26-35	5957-5958	,	_
26-36	5959-5963	flip	_
26-37	5964-5969	angle	_
26-38	5970-5971	=	_
26-39	5972-5975	85°	_
26-40	5976-5977	,	_
26-41	5978-5984	voxels	_
26-42	5985-5986	=	_
26-43	5987-5988	3	_
26-44	5989-5992	mm3	_
26-45	5993-5994	,	_
26-46	5995-5998	FOV	_
26-47	5999-6000	=	_
26-48	6001-6004	216	_
26-49	6005-6006	)	_
26-50	6007-6008	.	_

Text=Participants were instructed to remain still and keep their eyes open, while blinking normally.
27-1	6009-6021	Participants	_
27-2	6022-6026	were	_
27-3	6027-6037	instructed	_
27-4	6038-6040	to	_
27-5	6041-6047	remain	_
27-6	6048-6053	still	_
27-7	6054-6057	and	_
27-8	6058-6062	keep	_
27-9	6063-6068	their	_
27-10	6069-6073	eyes	_
27-11	6074-6078	open	_
27-12	6079-6080	,	_
27-13	6081-6086	while	_
27-14	6087-6095	blinking	_
27-15	6096-6104	normally	_
27-16	6105-6106	.	_

Text=Although no fixation image was used, participants with psychotic illness were monitored via eye-tracking video to ensure compliance during functional scans.
28-1	6107-6115	Although	_
28-2	6116-6118	no	_
28-3	6119-6127	fixation	_
28-4	6128-6133	image	_
28-5	6134-6137	was	_
28-6	6138-6142	used	_
28-7	6143-6144	,	_
28-8	6145-6157	participants	_
28-9	6158-6162	with	_
28-10	6163-6172	psychotic	_
28-11	6173-6180	illness	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
28-12	6181-6185	were	_
28-13	6186-6195	monitored	_
28-14	6196-6199	via	_
28-15	6200-6212	eye-tracking	_
28-16	6213-6218	video	_
28-17	6219-6221	to	_
28-18	6222-6228	ensure	_
28-19	6229-6239	compliance	_
28-20	6240-6246	during	_
28-21	6247-6257	functional	_
28-22	6258-6263	scans	_
28-23	6264-6265	.	_

Text=Software upgrades (VB13, VB15, VB17) occurred during data collection.
29-1	6266-6274	Software	_
29-2	6275-6283	upgrades	_
29-3	6284-6285	(	_
29-4	6286-6290	VB13	_
29-5	6291-6292	,	_
29-6	6293-6297	VB15	_
29-7	6298-6299	,	_
29-8	6300-6304	VB17	_
29-9	6305-6306	)	_
29-10	6307-6315	occurred	_
29-11	6316-6322	during	_
29-12	6323-6327	data	_
29-13	6328-6338	collection	_
29-14	6339-6340	.	_

Text=All results are reported after partialing out variance associated with coil, scanner (Harvard Bay 1, McLean Bay 1, MGH Bay 4, MGH Bay 8, and so forth), and software upgrade, as well as age, sex, handedness, race, and ethnicity.
30-1	6341-6344	All	_
30-2	6345-6352	results	_
30-3	6353-6356	are	_
30-4	6357-6365	reported	_
30-5	6366-6371	after	_
30-6	6372-6382	partialing	_
30-7	6383-6386	out	_
30-8	6387-6395	variance	_
30-9	6396-6406	associated	_
30-10	6407-6411	with	_
30-11	6412-6416	coil	_
30-12	6417-6418	,	_
30-13	6419-6426	scanner	_
30-14	6427-6428	(	_
30-15	6429-6436	Harvard	_
30-16	6437-6440	Bay	_
30-17	6441-6442	1	_
30-18	6443-6444	,	_
30-19	6445-6451	McLean	_
30-20	6452-6455	Bay	_
30-21	6456-6457	1	_
30-22	6458-6459	,	_
30-23	6460-6463	MGH	_
30-24	6464-6467	Bay	_
30-25	6468-6469	4	_
30-26	6470-6471	,	_
30-27	6472-6475	MGH	_
30-28	6476-6479	Bay	_
30-29	6480-6481	8	_
30-30	6482-6483	,	_
30-31	6484-6487	and	_
30-32	6488-6490	so	_
30-33	6491-6496	forth	_
30-34	6497-6498	)	_
30-35	6499-6500	,	_
30-36	6501-6504	and	_
30-37	6505-6513	software	_
30-38	6514-6521	upgrade	_
30-39	6522-6523	,	_
30-40	6524-6526	as	_
30-41	6527-6531	well	_
30-42	6532-6534	as	_
30-43	6535-6538	age	_
30-44	6539-6540	,	_
30-45	6541-6544	sex	_
30-46	6545-6546	,	_
30-47	6547-6557	handedness	_
30-48	6558-6559	,	_
30-49	6560-6564	race	_
30-50	6565-6566	,	_
30-51	6567-6570	and	_
30-52	6571-6580	ethnicity	_
30-53	6581-6582	.	_

Text=All treatment-seeking patient samples were collected on a 12-channel coil.
31-1	6583-6586	All	_
31-2	6587-6604	treatment-seeking	_
31-3	6605-6612	patient	_
31-4	6613-6620	samples	_
31-5	6621-6625	were	_
31-6	6626-6635	collected	_
31-7	6636-6638	on	_
31-8	6639-6640	a	_
31-9	6641-6651	12-channel	_
31-10	6652-6656	coil	_
31-11	6657-6658	.	_

Text=In the healthy comparison, participants and nontreatment-seeking individuals with unipolar depression 78.5 and 36.7% of the data were collected on a 12-channel coil, respectively.
32-1	6659-6661	In	_
32-2	6662-6665	the	_
32-3	6666-6673	healthy	_
32-4	6674-6684	comparison	_
32-5	6685-6686	,	_
32-6	6687-6699	participants	_
32-7	6700-6703	and	_
32-8	6704-6724	nontreatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
32-9	6725-6736	individuals	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
32-10	6737-6741	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
32-11	6742-6750	unipolar	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
32-12	6751-6761	depression	_
32-13	6762-6766	78.5	_
32-14	6767-6770	and	_
32-15	6771-6775	36.7	_
32-16	6776-6777	%	_
32-17	6778-6780	of	_
32-18	6781-6784	the	_
32-19	6785-6789	data	_
32-20	6790-6794	were	_
32-21	6795-6804	collected	_
32-22	6805-6807	on	_
32-23	6808-6809	a	_
32-24	6810-6820	12-channel	_
32-25	6821-6825	coil	_
32-26	6826-6827	,	_
32-27	6828-6840	respectively	_
32-28	6841-6842	.	_

Text=All reported analyses are consistent when separately considering only 12-channel and 32-channel coil data.
33-1	6843-6846	All	_
33-2	6847-6855	reported	_
33-3	6856-6864	analyses	_
33-4	6865-6868	are	_
33-5	6869-6879	consistent	_
33-6	6880-6884	when	_
33-7	6885-6895	separately	_
33-8	6896-6907	considering	_
33-9	6908-6912	only	_
33-10	6913-6923	12-channel	_
33-11	6924-6927	and	_
33-12	6928-6938	32-channel	_
33-13	6939-6943	coil	_
33-14	6944-6948	data	_
33-15	6949-6950	.	_

Text=The patient and healthy comparison samples did not differ in mean slice-based signal-to-noise [all patients: 172.4 ± 66.8; healthy comparison: 175.3 ± 51.2; F (1, 1,008) = 0.61, P = 0.43].
34-1	6951-6954	The	_
34-2	6955-6962	patient	_
34-3	6963-6966	and	_
34-4	6967-6974	healthy	_
34-5	6975-6985	comparison	_
34-6	6986-6993	samples	_
34-7	6994-6997	did	_
34-8	6998-7001	not	_
34-9	7002-7008	differ	_
34-10	7009-7011	in	_
34-11	7012-7016	mean	_
34-12	7017-7028	slice-based	_
34-13	7029-7044	signal-to-noise	_
34-14	7045-7046	[	_
34-15	7047-7050	all	_
34-16	7051-7059	patients	_
34-17	7060-7061	:	_
34-18	7062-7067	172.4	_
34-19	7068-7069	±	_
34-20	7070-7074	66.8	_
34-21	7075-7076	;	_
34-22	7077-7084	healthy	_
34-23	7085-7095	comparison	_
34-24	7096-7097	:	_
34-25	7098-7103	175.3	_
34-26	7104-7105	±	_
34-27	7106-7110	51.2	_
34-28	7111-7112	;	_
34-29	7113-7114	F	_
34-30	7115-7116	(	_
34-31	7117-7118	1	_
34-32	7119-7120	,	_
34-33	7121-7126	1,008	_
34-34	7127-7128	)	_
34-35	7129-7130	=	_
34-36	7131-7135	0.61	_
34-37	7136-7137	,	_
34-38	7138-7139	P	_
34-39	7140-7141	=	_
34-40	7142-7146	0.43	_
34-41	7147-7148	]	_
34-42	7149-7150	.	_

Text=Patients displayed a significantly greater number of micromovements (translations> 0.1 mm) during data collection [all patients: 25.5 ± 27.2; healthy comparison: 20.3 ± 24.7; F (1, 1,008) = 9.89, P ≤ 0.005].
35-1	7151-7159	Patients	_
35-2	7160-7169	displayed	_
35-3	7170-7171	a	_
35-4	7172-7185	significantly	_
35-5	7186-7193	greater	_
35-6	7194-7200	number	_
35-7	7201-7203	of	_
35-8	7204-7218	micromovements	_
35-9	7219-7220	(	_
35-10	7221-7233	translations	_
35-11	7234-7235	>	_
35-12	7236-7239	0.1	_
35-13	7240-7242	mm	_
35-14	7243-7244	)	_
35-15	7245-7251	during	_
35-16	7252-7256	data	_
35-17	7257-7267	collection	_
35-18	7268-7269	[	_
35-19	7270-7273	all	_
35-20	7274-7282	patients	_
35-21	7283-7284	:	_
35-22	7285-7289	25.5	_
35-23	7290-7291	±	_
35-24	7292-7296	27.2	_
35-25	7297-7298	;	_
35-26	7299-7306	healthy	_
35-27	7307-7317	comparison	_
35-28	7318-7319	:	_
35-29	7320-7324	20.3	_
35-30	7325-7326	±	_
35-31	7327-7331	24.7	_
35-32	7332-7333	;	_
35-33	7334-7335	F	_
35-34	7336-7337	(	_
35-35	7338-7339	1	_
35-36	7340-7341	,	_
35-37	7342-7347	1,008	_
35-38	7348-7349	)	_
35-39	7350-7351	=	_
35-40	7352-7356	9.89	_
35-41	7357-7358	,	_
35-42	7359-7360	P	_
35-43	7361-7362	≤	_
35-44	7363-7368	0.005	_
35-45	7369-7370	]	_
35-46	7371-7372	.	_

Text=The reported group-level effects are consistent when incorporating mean slice-based SNR and micromovement counts as model covariates.
36-1	7373-7376	The	_
36-2	7377-7385	reported	_
36-3	7386-7397	group-level	_
36-4	7398-7405	effects	_
36-5	7406-7409	are	_
36-6	7410-7420	consistent	_
36-7	7421-7425	when	_
36-8	7426-7439	incorporating	_
36-9	7440-7444	mean	_
36-10	7445-7456	slice-based	_
36-11	7457-7460	SNR	_
36-12	7461-7464	and	_
36-13	7465-7478	micromovement	_
36-14	7479-7485	counts	_
36-15	7486-7488	as	_
36-16	7489-7494	model	_
36-17	7495-7505	covariates	_
36-18	7506-7507	.	_

Text=Preprocessing.
37-1	7508-7521	Preprocessing	_
37-2	7522-7523	.	_

Text=Data were analyzed with a series of steps common to intrinsic connectivity analyses and further elaborated in Holmes et al.
38-1	7524-7528	Data	_
38-2	7529-7533	were	_
38-3	7534-7542	analyzed	_
38-4	7543-7547	with	_
38-5	7548-7549	a	_
38-6	7550-7556	series	_
38-7	7557-7559	of	_
38-8	7560-7565	steps	_
38-9	7566-7572	common	_
38-10	7573-7575	to	_
38-11	7576-7585	intrinsic	_
38-12	7586-7598	connectivity	_
38-13	7599-7607	analyses	_
38-14	7608-7611	and	_
38-15	7612-7619	further	_
38-16	7620-7630	elaborated	_
38-17	7631-7633	in	_
38-18	7634-7640	Holmes	_
38-19	7641-7643	et	_
38-20	7644-7646	al	_
38-21	7647-7648	.	_

Text=and Yeo et al .. Preprocessing included discarding the first four volumes of each run to allow for T1-equilibration effects, compensating for slice acquisition-dependent time shifts per volume, and correcting for head motion using rigid body translation and rotation.
39-1	7649-7652	and	_
39-2	7653-7656	Yeo	_
39-3	7657-7659	et	_
39-4	7660-7662	al	_
39-5	7663-7665	..	_
39-6	7666-7679	Preprocessing	_
39-7	7680-7688	included	_
39-8	7689-7699	discarding	_
39-9	7700-7703	the	_
39-10	7704-7709	first	_
39-11	7710-7714	four	_
39-12	7715-7722	volumes	_
39-13	7723-7725	of	_
39-14	7726-7730	each	_
39-15	7731-7734	run	_
39-16	7735-7737	to	_
39-17	7738-7743	allow	_
39-18	7744-7747	for	_
39-19	7748-7764	T1-equilibration	_
39-20	7765-7772	effects	_
39-21	7773-7774	,	_
39-22	7775-7787	compensating	_
39-23	7788-7791	for	_
39-24	7792-7797	slice	_
39-25	7798-7819	acquisition-dependent	_
39-26	7820-7824	time	_
39-27	7825-7831	shifts	_
39-28	7832-7835	per	_
39-29	7836-7842	volume	_
39-30	7843-7844	,	_
39-31	7845-7848	and	_
39-32	7849-7859	correcting	_
39-33	7860-7863	for	_
39-34	7864-7868	head	_
39-35	7869-7875	motion	_
39-36	7876-7881	using	_
39-37	7882-7887	rigid	_
39-38	7888-7892	body	_
39-39	7893-7904	translation	_
39-40	7905-7908	and	_
39-41	7909-7917	rotation	_
39-42	7918-7919	.	_

Text=Additional steps involved the removal of constant offset and linear trends over each run and the use of a temporal filter to retain frequencies below 0.08 Hz.
40-1	7920-7930	Additional	_
40-2	7931-7936	steps	_
40-3	7937-7945	involved	_
40-4	7946-7949	the	_
40-5	7950-7957	removal	_
40-6	7958-7960	of	_
40-7	7961-7969	constant	_
40-8	7970-7976	offset	_
40-9	7977-7980	and	_
40-10	7981-7987	linear	_
40-11	7988-7994	trends	_
40-12	7995-7999	over	_
40-13	8000-8004	each	_
40-14	8005-8008	run	_
40-15	8009-8012	and	_
40-16	8013-8016	the	_
40-17	8017-8020	use	_
40-18	8021-8023	of	_
40-19	8024-8025	a	_
40-20	8026-8034	temporal	_
40-21	8035-8041	filter	_
40-22	8042-8044	to	_
40-23	8045-8051	retain	_
40-24	8052-8063	frequencies	_
40-25	8064-8069	below	_
40-26	8070-8074	0.08	_
40-27	8075-8077	Hz	_
40-28	8078-8079	.	_

Text=Sources of spurious variance, along with their temporal derivatives, were removed through linear regression.
41-1	8080-8087	Sources	_
41-2	8088-8090	of	_
41-3	8091-8099	spurious	_
41-4	8100-8108	variance	_
41-5	8109-8110	,	_
41-6	8111-8116	along	_
41-7	8117-8121	with	_
41-8	8122-8127	their	_
41-9	8128-8136	temporal	_
41-10	8137-8148	derivatives	_
41-11	8149-8150	,	_
41-12	8151-8155	were	_
41-13	8156-8163	removed	_
41-14	8164-8171	through	_
41-15	8172-8178	linear	_
41-16	8179-8189	regression	_
41-17	8190-8191	.	_

Text=These included six parameters obtained by correction for rigid-body head motion, the signal averaged over the whole brain, the signal averaged over the ventricles, and the signal averaged over the deep cerebral white matter.
42-1	8192-8197	These	_
42-2	8198-8206	included	_
42-3	8207-8210	six	_
42-4	8211-8221	parameters	_
42-5	8222-8230	obtained	_
42-6	8231-8233	by	_
42-7	8234-8244	correction	_
42-8	8245-8248	for	_
42-9	8249-8259	rigid-body	_
42-10	8260-8264	head	_
42-11	8265-8271	motion	_
42-12	8272-8273	,	_
42-13	8274-8277	the	_
42-14	8278-8284	signal	_
42-15	8285-8293	averaged	_
42-16	8294-8298	over	_
42-17	8299-8302	the	_
42-18	8303-8308	whole	_
42-19	8309-8314	brain	_
42-20	8315-8316	,	_
42-21	8317-8320	the	_
42-22	8321-8327	signal	_
42-23	8328-8336	averaged	_
42-24	8337-8341	over	_
42-25	8342-8345	the	_
42-26	8346-8356	ventricles	_
42-27	8357-8358	,	_
42-28	8359-8362	and	_
42-29	8363-8366	the	_
42-30	8367-8373	signal	_
42-31	8374-8382	averaged	_
42-32	8383-8387	over	_
42-33	8388-8391	the	_
42-34	8392-8396	deep	_
42-35	8397-8405	cerebral	_
42-36	8406-8411	white	_
42-37	8412-8418	matter	_
42-38	8419-8420	.	_

Text=Functional data were first aligned to the structural image using the FreeSurfer software package, smoothed using a 6-mm kernel applied in surface space, and down-sampled to a 4-mm mesh Yeo et al .. Functional Parcellation.
43-1	8421-8431	Functional	_
43-2	8432-8436	data	_
43-3	8437-8441	were	_
43-4	8442-8447	first	_
43-5	8448-8455	aligned	_
43-6	8456-8458	to	_
43-7	8459-8462	the	_
43-8	8463-8473	structural	_
43-9	8474-8479	image	_
43-10	8480-8485	using	_
43-11	8486-8489	the	_
43-12	8490-8500	FreeSurfer	_
43-13	8501-8509	software	_
43-14	8510-8517	package	_
43-15	8518-8519	,	_
43-16	8520-8528	smoothed	_
43-17	8529-8534	using	_
43-18	8535-8536	a	_
43-19	8537-8541	6-mm	_
43-20	8542-8548	kernel	_
43-21	8549-8556	applied	_
43-22	8557-8559	in	_
43-23	8560-8567	surface	_
43-24	8568-8573	space	_
43-25	8574-8575	,	_
43-26	8576-8579	and	_
43-27	8580-8592	down-sampled	_
43-28	8593-8595	to	_
43-29	8596-8597	a	_
43-30	8598-8602	4-mm	_
43-31	8603-8607	mesh	_
43-32	8608-8611	Yeo	_
43-33	8612-8614	et	_
43-34	8615-8617	al	_
43-35	8618-8620	..	_
43-36	8621-8631	Functional	_
43-37	8632-8644	Parcellation	_
43-38	8645-8646	.	_

Text=Cortical functional coupling matrices were computed for each participant, across all available regions within the 17 network functional parcellation of Yeo et al.
44-1	8647-8655	Cortical	_
44-2	8656-8666	functional	_
44-3	8667-8675	coupling	_
44-4	8676-8684	matrices	_
44-5	8685-8689	were	_
44-6	8690-8698	computed	_
44-7	8699-8702	for	_
44-8	8703-8707	each	_
44-9	8708-8719	participant	_
44-10	8720-8721	,	_
44-11	8722-8728	across	_
44-12	8729-8732	all	_
44-13	8733-8742	available	_
44-14	8743-8750	regions	_
44-15	8751-8757	within	_
44-16	8758-8761	the	_
44-17	8762-8764	17	_
44-18	8765-8772	network	_
44-19	8773-8783	functional	_
44-20	8784-8796	parcellation	_
44-21	8797-8799	of	_
44-22	8800-8803	Yeo	_
44-23	8804-8806	et	_
44-24	8807-8809	al	_
44-25	8810-8811	.	_

Text=(Fig.
45-1	8812-8813	(	_
45-2	8814-8817	Fig	_
45-3	8818-8819	.	_

Text=1A).
46-1	8820-8822	1A	_
46-2	8823-8824	)	_
46-3	8825-8826	.	_

Text=This parcellation consisted of 122 cortical regions composed of 61 roughly symmetric territories in the left and right hemispheres.
47-1	8827-8831	This	_
47-2	8832-8844	parcellation	_
47-3	8845-8854	consisted	_
47-4	8855-8857	of	_
47-5	8858-8861	122	_
47-6	8862-8870	cortical	_
47-7	8871-8878	regions	_
47-8	8879-8887	composed	_
47-9	8888-8890	of	_
47-10	8891-8893	61	_
47-11	8894-8901	roughly	_
47-12	8902-8911	symmetric	_
47-13	8912-8923	territories	_
47-14	8924-8926	in	_
47-15	8927-8930	the	_
47-16	8931-8935	left	_
47-17	8936-8939	and	_
47-18	8940-8945	right	_
47-19	8946-8957	hemispheres	_
47-20	8958-8959	.	_

Text=Correlation matrices were constructed to include all regional pairs arranged by network membership.
48-1	8960-8971	Correlation	_
48-2	8972-8980	matrices	_
48-3	8981-8985	were	_
48-4	8986-8997	constructed	_
48-5	8998-9000	to	_
48-6	9001-9008	include	_
48-7	9009-9012	all	_
48-8	9013-9021	regional	_
48-9	9022-9027	pairs	_
48-10	9028-9036	arranged	_
48-11	9037-9039	by	_
48-12	9040-9047	network	_
48-13	9048-9058	membership	_
48-14	9059-9060	.	_

Text=Pearson correlation coefficients were computed between each regional fMRI time course, averaged across all vertices within the region, and the mean fMRI time course for every other region (Fig.
49-1	9061-9068	Pearson	_
49-2	9069-9080	correlation	_
49-3	9081-9093	coefficients	_
49-4	9094-9098	were	_
49-5	9099-9107	computed	_
49-6	9108-9115	between	_
49-7	9116-9120	each	_
49-8	9121-9129	regional	_
49-9	9130-9134	fMRI	_
49-10	9135-9139	time	_
49-11	9140-9146	course	_
49-12	9147-9148	,	_
49-13	9149-9157	averaged	_
49-14	9158-9164	across	_
49-15	9165-9168	all	_
49-16	9169-9177	vertices	_
49-17	9178-9184	within	_
49-18	9185-9188	the	_
49-19	9189-9195	region	_
49-20	9196-9197	,	_
49-21	9198-9201	and	_
49-22	9202-9205	the	_
49-23	9206-9210	mean	_
49-24	9211-9215	fMRI	_
49-25	9216-9220	time	_
49-26	9221-9227	course	_
49-27	9228-9231	for	_
49-28	9232-9237	every	_
49-29	9238-9243	other	_
49-30	9244-9250	region	_
49-31	9251-9252	(	_
49-32	9253-9256	Fig	_
49-33	9257-9258	.	_

Text=1 B–D).
50-1	9259-9260	1	_
50-2	9261-9264	B–D	_
50-3	9265-9266	)	_
50-4	9267-9268	.	_

Text=Correlation values were z-transformed to increase normality of the correlation distribution and compared across groups using an ANOVA after linear regression of nuisance variables.
51-1	9269-9280	Correlation	_
51-2	9281-9287	values	_
51-3	9288-9292	were	_
51-4	9293-9306	z-transformed	_
51-5	9307-9309	to	_
51-6	9310-9318	increase	_
51-7	9319-9328	normality	_
51-8	9329-9331	of	_
51-9	9332-9335	the	_
51-10	9336-9347	correlation	_
51-11	9348-9360	distribution	_
51-12	9361-9364	and	_
51-13	9365-9373	compared	_
51-14	9374-9380	across	_
51-15	9381-9387	groups	_
51-16	9388-9393	using	_
51-17	9394-9396	an	_
51-18	9397-9402	ANOVA	_
51-19	9403-9408	after	_
51-20	9409-9415	linear	_
51-21	9416-9426	regression	_
51-22	9427-9429	of	_
51-23	9430-9438	nuisance	_
51-24	9439-9448	variables	_
51-25	9449-9450	.	_

Text=Reported tests survived correction for multiple comparisons using a family-wise error rate (Bonferroni procedure) of P ≤ 0.05 or FDR of q ≤ 0.05.
52-1	9451-9459	Reported	_
52-2	9460-9465	tests	_
52-3	9466-9474	survived	_
52-4	9475-9485	correction	_
52-5	9486-9489	for	_
52-6	9490-9498	multiple	_
52-7	9499-9510	comparisons	_
52-8	9511-9516	using	_
52-9	9517-9518	a	_
52-10	9519-9530	family-wise	_
52-11	9531-9536	error	_
52-12	9537-9541	rate	_
52-13	9542-9543	(	_
52-14	9544-9554	Bonferroni	_
52-15	9555-9564	procedure	_
52-16	9565-9566	)	_
52-17	9567-9569	of	_
52-18	9570-9571	P	_
52-19	9572-9573	≤	_
52-20	9574-9578	0.05	_
52-21	9579-9581	or	_
52-22	9582-9585	FDR	_
52-23	9586-9588	of	_
52-24	9589-9590	q	_
52-25	9591-9592	≤	_
52-26	9593-9597	0.05	_
52-27	9598-9599	.	_

Text=Readers should note that caution is warranted when interpreting group differences in within-network connectivity for subnetworks with limited numbers of parcels (e.g., frontoparietal control C and default D).
53-1	9600-9607	Readers	_
53-2	9608-9614	should	_
53-3	9615-9619	note	_
53-4	9620-9624	that	_
53-5	9625-9632	caution	_
53-6	9633-9635	is	_
53-7	9636-9645	warranted	_
53-8	9646-9650	when	_
53-9	9651-9663	interpreting	_
53-10	9664-9669	group	_
53-11	9670-9681	differences	_
53-12	9682-9684	in	_
53-13	9685-9699	within-network	_
53-14	9700-9712	connectivity	_
53-15	9713-9716	for	_
53-16	9717-9728	subnetworks	_
53-17	9729-9733	with	_
53-18	9734-9741	limited	_
53-19	9742-9749	numbers	_
53-20	9750-9752	of	_
53-21	9753-9760	parcels	_
53-22	9761-9762	(	_
53-23	9763-9767	e.g.	_
53-24	9768-9769	,	_
53-25	9770-9784	frontoparietal	_
53-26	9785-9792	control	_
53-27	9793-9794	C	_
53-28	9795-9798	and	_
53-29	9799-9806	default	_
53-30	9807-9808	D	_
53-31	9809-9810	)	_
53-32	9811-9812	.	_

